Mechanisms of SSRI Therapy and Discontinuation
The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Abstract
SSRIs are one of the most widely used drug therapies in primary care and psychiatry, and central to the management of the most common mental health problems in today's society. Despite this, SSRIs suffer from a slow onset of therapeutic effect and relatively poor efficacy as well as adverse effects, with recent concerns being focused on a disabling SSRI discontinuation syndrome. The mechanism underpinning their therapeutic effect has long shifted away from thinking that SSRIs act simply by increasing 5-HT in the synapse. Rather, a current popular view is that increased 5-HT is just the beginning of a series of complex downstream signalling events, which trigger changes in neural plasticity at the functional and structural level. These changes in plasticity are then thought to interact with neuropsychological processes to enhance re-learning of emotional experiences that ultimately brings about changes in mood. This compelling view of SSRI action is underpinning attempts to understand fast-acting antidepressants, such as ketamine and psychedelic drugs, and aid the development of future therapies. An important gap in the theory is evidence that changes in plasticity are causally linked to relevant behavioural effects. Also, predictions that the SSRI-induced neural plasticity might have applicability in other areas of medicine have not yet been borne out. In contrast to the sophisticated view of the antidepressant action of SSRIs, the mechanism underpinning SSRI discontinuation…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
for the ENIGMA-Major Depressive Disorder Working Group, Schmaal, L., Veltman, D. J., van Erp, T. G. M., Sämann, P. G., Frodl, T., Jahanshad, N., Loehrer, E., Tiemeier, H., Hofman, A., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.69 · Cited by 1,172
Current advances and trends in the treatment of depression
Blier, P., & de Montigny, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90315-8 · Cited by 1,113
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
The serotonin theory of depression: a systematic umbrella review of the evidence
Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01661-0 · Cited by 960
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Delgado, P. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810170011002 · Cited by 924
The antidepressant fluoxetine restores plasticity in the adult visual cortex
Vetencourt, J. F. M., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., F. O'Leary, O., Castrén, E., & Maffei, L. (2008) · Science · doi:10.1126/science.1150516 · Cited by 890
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Early-Life Blockade of the 5-HT Transporter Alters Emotional Behavior in Adult Mice
Ansorge, M. S., Zhou, M., Lira, A., Hen, R., & Gingrich, J. A. (2004) · Science · doi:10.1126/science.1101678 · Cited by 817
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
Artigas, F., Romero, L., de Montigny, C., & Blier, P. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10037-0 · Cited by 655
A third vesicular glutamate transporter expressed by cholinergic and serotoninergic neurons
Gras, C., Herzog, E., Bellenchi, G. C., Bernard, V., Ravassard, P., Pohl, M., Gasnier, B., Giros, B., & El Mestikawy, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05442.2002 · Cited by 639
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
How do antidepressants work? New perspectives for refining future treatment approaches
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616
Castrén, E. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1629 · Cited by 563
Harmer, C. J., Goodwin, G. M., & Cowen, P. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051193 · Cited by 542
Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
Castrén, E., & Monteggia, L. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.008 · Cited by 540
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517
Antidepressants and neuroplasticity
D'Sa, C., & Duman, R. S. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01203.x · Cited by 513
The neurobiology of opioid dependence: implications for treatment
Kosten, T., & George, T. (2002) · Science & Practice Perspectives · doi:10.1151/spp021113 · Cited by 505
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
Vargas, M. V., Dunlap, L. E., Dong, C., Carter, S. J., Tombari, R. J., Jami, S. A., Cameron, L. P., Patel, S. D., Hennessey, J. J., Saeger, H. N., et al. (2023) · Science · doi:10.1126/science.adf0435 · Cited by 489
Lower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484
Glutamatergic substrates of drug addiction and alcoholism
Gass, J. T., & Olive, M. F. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.039 · Cited by 484
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01316-5 · Cited by 478
A non-hallucinogenic psychedelic analogue with therapeutic potential
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., et al. (2021) · Nature · doi:10.1038/s41586-020-3008-z · Cited by 473
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Tartt, A. N., Mariani, M. B., Hen, R., Mann, J. J., & Boldrini, M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01520-y · Cited by 408
Bourin, M., Chue, P., & Guillon, Y. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00189.x · Cited by 408
Is it time to reassess the BDNF hypothesis of depression?
Groves, J. O. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002075 · Cited by 404
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B., & Thompson, S. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022489118 · Cited by 378
The Role of CREB in Depression and Antidepressant Treatment
Blendy, J. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.003 · Cited by 365
Clinical Pharmacokinetics of Fluoxetine
Altamura, A. C., Moro, A. R., & Percudani, M. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426030-00004 · Cited by 336
Levinson-Castiel, R., Merlob, P., Linder, N., Sirota, L., & Klinger, G. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.2.173 · Cited by 329
Gartside, S. E., Umbers, V., Hajós, M., & Sharp, T. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15919.x · Cited by 312
Self-citationHolick, K. A., Lee, D. C., Hen, R., & Dulawa, S. C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301399 · Cited by 310
The neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 302
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107933 · Cited by 278
Epigenetic Mechanisms of Depression and Antidepressant Action
Vialou, V., Feng, J., Robison, A. J., & Nestler, E. J. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134540 · Cited by 277
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery
Mead, G. E., Hsieh, C.-F., Lee, R., Kutlubaev, M. A., Claxton, A., Hankey, G. J., & Hackett, M. L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009286.pub2 · Cited by 249
Long-term antidepressant use: patient perspectives of benefits and adverse effects
Cartwright, C., Gibson, K., Read, J., Cowan, O., & Dehar, T. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s110632 · Cited by 242
The role of serotonin receptor subtypes in treating depression: a review of animal studies
Carr, G. V., & Lucki, I. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2097-z · Cited by 239
Jovanovic, H., Lundberg, J., Karlsson, P., Cerin, Å., Saijo, T., Varrone, A., Halldin, C., & Nordström, A.-L. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.10.016 · Cited by 231
Central 5-HT receptors and their function; present and future
Sharp, T., & Barnes, N. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108155 · Cited by 231
Self-citationMacQueen, G. M., Ramakrishman, K., Croll, S. D., Siuciak, J. A., Yu, G., Young, T., & Fahnestock, M. (2001) · Behavioral Neuroscience · doi:10.1037//0735-7044.115.5.1145 · Cited by 211
Elizalde, N., Gil-Bea, F. J., Ramírez, M. J., Aisa, B., Lasheras, B., Del Rio, J., & Tordera, R. M. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1035-1 · Cited by 200
The promises and perils of psychedelic pharmacology for psychiatry
McClure-Begley, T. D., & Roth, B. L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00421-7 · Cited by 194
Anton, R. F., Latham, P., Voronin, K., Book, S., Hoffman, M., Prisciandaro, J., & Bristol, E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0249 · Cited by 186
Cowen, P. J., & Nutt, D. J. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90550-5 · Cited by 181
The serotonin transporter in psychiatric disorders: insights from PET imaging
Spies, M., Knudsen, G. M., Lanzenberger, R., & Kasper, S. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00232-1 · Cited by 177
Neurochemical mechanisms underlying alcohol withdrawal.
Littleton, J. (1998) · PubMed Central · Cited by 172
Antidepressant Effects of Fibroblast Growth Factor-2 in Behavioral and Cellular Models of Depression
Elsayed, M., Banasr, M., Duric, V., Fournier, N. M., Licznerski, P., & Duman, R. S. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.003 · Cited by 169
A non-hallucinogenic LSD analog with therapeutic potential for mood disorders
Lewis, V., Bonniwell, E. M., Lanham, J. K., Ghaffari, A., Sheshbaradaran, H., Cao, A. B., Calkins, M. M., Bautista-Carro, M. A., Arsenault, E., Telfer, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112203 · Cited by 164
Hayward, G., Goodwin, G. M., Cowen, P. J., & Harmer, C. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.016 · Cited by 162
VEGF as a potential target for therapeutic intervention in depression
Warner‐Schmidt, J. L., & Duman, R. S. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.10.013 · Cited by 159
Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression
Licznerski, P., & Duman, R. S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.057 · Cited by 157
Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents
Klein, M. E., Chandra, J., Sheriff, S., & Malinow, R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916570117 · Cited by 156
Development of pharmacotherapies for drug addiction: a Rosetta stone approach
Koob, G. F., Kenneth Lloyd, G., & Mason, B. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2828 · Cited by 154
5-HT and depression: is the glass half-full?
Sharp, T., & Cowen, P. J. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.003 · Cited by 153
Self-citationRiad, M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0950-04.2004 · Cited by 141
Control of amygdala circuits by 5-HT neurons via 5-HT and glutamate cotransmission
Sengupta, A., Bocchio, M., Bannerman, D. M., Sharp, T., & Capogna, M. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2238-16.2016 · Cited by 136
Distribution of vesicular glutamate transporters in the human brain
Vigneault, É., Poirel, O., Riad, M., Prud'homme, J., Dumas, S., Turecki, G., Fasano, C., Mechawar, N., & El Mestikawy, S. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00023 · Cited by 130
Gelenberg, A. J., & Chesen, C. L. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1002 · Cited by 127
Parsey, R. V., KENT, J. M., Oquendo, M. A., Richards, M., Pratap, M., Cooper, T. B., Arango, V., & Mann, J. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.010 · Cited by 120
Recognising and managing antidepressant discontinuation symptoms
Haddad, P. M., & Anderson, I. M. (2007) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.105.001966 · Cited by 109
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Renoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107
Newer antidepressants and the discontinuation syndrome.
Haddad, P. M. (1997) · PubMed · Cited by 101
Baldwin, D. S., Cooper, J. A., Huusom, A. K. T., & Hindmarch, I. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194377.88330.1d · Cited by 100
Sex-Specific Effects of Chronic Fluoxetine Treatment on Neuroplasticity and Pharmacokinetics in Mice
Hodes, G. E., Hill‐Smith, T. E., Suckow, R. F., Cooper, T. B., & Lucki, I. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158717 · Cited by 98
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery
Legg, L. A., Rudberg, A.-S., Hua, X., Wu, S., Hackett, M. L., Tilney, R., Lindgren, L., Kutlubaev, M. A., Hsieh, C.-F., Barugh, A. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009286.pub4 · Cited by 97
Ohmura, Y., Tsutsui-Kimura, I., Sasamori, H., Nebuka, M., Nishitani, N., Tanaka, K. F., Yamanaka, A., & Yoshioka, M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107703 · Cited by 92
Jauhar, S., Arnone, D., Baldwin, D. S., Bloomfield, M., Browning, M. D., Cleare, A. J., Corlett, P. R., Deakin, J. F. W., Erritzøe, D., Fu, C. H. Y., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02095-y · Cited by 91
Sexually Dimorphic Serotonergic Dysfunction in a Mouse Model of Huntington's Disease and Depression
Renoir, T., Zajac, M. S., Du, X., Pang, T. Y., Leang, L., Chevarin, C., Lanfumey, L., & Hannan, A. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022133 · Cited by 90
Erritzoe, D., Godlewska, B. R., Rizzo, G., Searle, G. E., Agnorelli, C., Lewis, Y., Ashok, A. H., Colasanti, A., Boura, I., Farrell, C., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.10.012 · Cited by 90
Lerner, A., & Klein, M. (2019) · Brain Communications · doi:10.1093/braincomms/fcz025 · Cited by 89
Lindefors, N., Brodin, E., & METSIS, M. L. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00550-o · Cited by 86
Huang, G.-J., Bannerman, D. M., & Flint, J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002104 · Cited by 86
iPlasticity: Induced juvenile‐like plasticity in the adult brain as a mechanism of antidepressants
Umemori, J., Winkel, F., Didio, G., Llach Pou, M., & Castrén, E. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12683 · Cited by 80
Hajós‐Korcsok, É., McTavish, S. F. B., & Sharp, T. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00723-8 · Cited by 79
Self-citationKinetics of citalopram in test animals; drug exposure in safety studies
Overø, K. F. (1982) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(82)80180-2 · Cited by 78
Yonkers, K. A., Kornstein, S. G., Gueorguieva, R., Merry, B., Van Steenburgh, K., & Altemus, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1472 · Cited by 78
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data
Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2023) · CNS Drugs · doi:10.1007/s40263-022-00960-y · Cited by 76
Monoamine depletion studies: implications for antidepressant discontinuation syndrome.
Delgado, P. L. (2006) · PubMed · Cited by 73
When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips
Jha, M. K., Rush, A. J., & Trivedi, M. H. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18060692 · Cited by 73
Reboxetine: a review of antidepressant tolerability.
Mucci, M. (1997) · PubMed · Cited by 70
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy
Navari, R. M. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.03.020 · Cited by 69
Pharmacological Mechanism of the Non-hallucinogenic 5-HT 2A Agonist Ariadne and Analogs
Cunningham, M. J., Bock, H. A., Serrano, I. C., Bechand, B., Vidyadhara, D. J., Bonniwell, E. M., Lankri, D., Duggan, P., Nazarova, A. L., Cao, A. B., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00597 · Cited by 67
Gastaldon, C., Schoretsanitis, G., Arzenton, E., Raschi, E., Papola, D., Ostuzzi, G., Moretti, U., Seifritz, E., Kane, J. M., Trifirò, G., et al. (2022) · Drug Safety · doi:10.1007/s40264-022-01246-4 · Cited by 64
Wernicke, J. F., Adler, L., Spencer, T., West, S. A., Allen, A. J., Heiligenstein, J., Milton, D., Ruff, D., Brown, W. J., Kelsey, D., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104907.75206.c2 · Cited by 61
Neuropharmacological basis of vestibular system disorder treatment
Soto, E., Vega, R., & Seseña, E. (2013) · Journal of Vestibular Research · doi:10.3233/ves-130494 · Cited by 60
Bridging Rapid and Sustained Antidepressant Effects of Ketamine
Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59
New insights on the antidepressant discontinuation syndrome
Harvey, B. H., & Slabbert, F. N. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2429 · Cited by 58
Trouvin, J., Gardier, A. M., Chanut, E., Pagès, N., & Jacquot, C. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90116-k · Cited by 58
Pei, Q., Tordera, R. M., Sprakes, M., & Sharp, T. (2003) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.017 · Cited by 51
Self-citationDual serotonergic signals: a key to understanding paradoxical effects?
Fischer, A. G., Jocham, G., & Ullsperger, M. (2014) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2014.11.004 · Cited by 51
BDNF receptor TrkB as the mediator of the antidepressant drug action
Casarotto, P., Umemori, J., & Castrén, E. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1032224 · Cited by 50
Kreilgaard, M., Smith, D. G., Brennum, L. T., & Sánchez, C. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.243 · Cited by 49
Physiologic mechanisms underlying the antidepressant discontinuation syndrome.
Blier, P., & Tremblay, P. (2006) · PubMed · Cited by 49
Malberg, J. E., Hen, R., & Madsen, T. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.01.010 · Cited by 49
Jennings, K. A., Sheward, W. J., Harmar, A. J., & Sharp, T. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.001 · Cited by 48
Self-citationJennings, K. A., Lesch, K., Sharp, T., & Cragg, S. J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07001.x · Cited by 46
Self-citationStenfors, C., & Ross, S. B. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02138-0 · Cited by 46
Barton, C. L., & Hutson, P. H. (1999) · Synapse · doi:10.1002/(sici)1098-2396(199901)31:1<13::aid-syn3>3.0.co;2-y · Cited by 41
Bosker, F. J., Tanke, M. A. C., Jongsma, M. E., Cremers, T. I. F. H., Jagtman, E., Pietersen, C. Y., van der Hart, M. G. C., Gladkevich, A. V., Kema, I. P., Westerink, B. H. C., et al. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.10.001 · Cited by 40
Nackenoff, A. G., Moussa‐Tooks, A. B., McMeekin, A. M., Veenstra-VanderWeele, J. M., & Blakely, R. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.335 · Cited by 39
Murata, Y., Kobayashi, D., Imuta, N., Haraguchi, K., Ieiri, I., Nishimura, R., Koyama, S., & Mine, K. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c8ae80 · Cited by 37
Venlafaxine:a novel antidepressant compound
Schweizer, E. E., Thielen, R. J., & Frazer, A. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.1.65 · Cited by 37
Molecular and Cellular Mechanisms of Antidepressant Action
Sharp, T. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_216 · Cited by 36
Self-citationBouët, V., Klomp, A., Fréret, T., Wylezinska, M., Lopez-Tremoleda, J., Dauphin, F., Boulouard, M., Booij, J., Gsell, W., & Reneman, L. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2580-1 · Cited by 36
Plasticity in mental health: A network theory
Branchi, I. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104691 · Cited by 35
(2006) · PubMed · Cited by 33
Antidepressants, withdrawal, and addiction; where are we now?
Jauhar, S., Hayes, J., Goodwin, G. M., Baldwin, D. S., Cowen, P. J., & Nutt, D. J. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845799 · Cited by 31
Strekalova, T. V., Anthony, D. C., Dolgov, O., Anokhin, K. V., Kubatiev, A. A., Steinbusch, H. W. M., & Schroeter, C. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.02.015 · Cited by 29
Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT
Duffy, L., Clarke, C. S., Lewis, G., Marston, L., Freemantle, N., Gilbody, S. M., Hunter, R. M., Kendrick, T., Kessler, D. S., King, M., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25690 · Cited by 27
Jennings, K. A., Licht, C. L., Bruce, A., Lesch, K., Knudsen, G. M., & Sharp, T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001258 · Cited by 26
Self-citationRebound activation of 5-HT neurons following SSRI discontinuation
Collins, H., Gullino, L. S., Ozdemir, D., Lazarenco, C., Sudarikova, Y., Daly, E., Pilar-Cuéllar, F., Pinacho, R., Bannerman, D. M., & Sharp, T. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01857-8 · Cited by 26
Self-citationDo antidepressants cause dependence?
Haddad, P. M. (2005) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00006254 · Cited by 24
Lagas, A. K., Black, J. M., Russell, B. R., Kydd, R. R., & Thompson, B. S. (2019) · Neural Plasticity · doi:10.1155/2019/5857243 · Cited by 23
Enhanced discriminative aversive learning and amygdala responsivity in 5-HT transporter mutant mice
Lima, J., Sharp, T., Bannerman, D. M., & McHugh, S. B. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0476-8 · Cited by 20
Self-citationEffect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice
Collins, H. M., Pinacho, R., Ozdemir, D., Bannerman, D. M., & Sharp, T. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221093032 · Cited by 15
Self-citationCollins, H. M., Pinacho, R., Tam, S. K. E., Sharp, T., Bannerman, D. M., & Peirson, S. N. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06442-3 · Cited by 15
Self-citationAntidepressant Discontinuation: In Need of Scientific Evidence
Vinkers, C. H., Ruhé, H. G., & Penninx, B. W. J. H. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001460 · Cited by 11
Cosci, F., Chouinard, V., & Chouinard, G. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000530692 · Cited by 7
Warlick, H., Leon, L., Patel, R., Filoramo, S., Knipe, R., Joubran, E., Levy, A., Nguyen, H., & Rey, J. A. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08110-9 · Cited by 6
Rebound activation of 5-HT neurons following SSRI discontinuationPreprint
Collins, H. M., Gullino, L. S., Ozdemir, D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.23.558888 · Cited by 1
Self-citation
Cited by
From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation
Krasner, H., Ong, C. V., Hewitt, P., & Vida, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073219 · Cited by 42
“Additionally, SSRIs are notorious for their required lengthy trial period before seeing therapeutic effects, as well as the litany of side effects associated with medication use, discontinuation, and abrupt cessation [256].”
Zhang, Y., Wang, N., Zhang, L., Zhuang, Y., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2025) · MedComm · doi:10.1002/mco2.70383 · Cited by 59
Trends in research on novel antidepressant treatments
Zelek-Molik, A., & Litwa, E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1544795 · Cited by 35
“Among these, SSRIs are the most commonly used today, as they primarily address the hypoactivity of monoamine neurotransmitter systems (Sharp and Collins, 2023).”
Цейликман, В. Э., Tseilikman, O. B., Karpenko, M. N., Traktirov, D. S., Obukhova, D. A., Shatilov, V. A., Zhukov, M. S., Валерьевич, М. Г., Yegorov, O. N., Aristov, M. R., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12112455 · Cited by 24
“Moreover, the long-term use of SSRIs is associated with several adverse effects, such as impaired spermatogenesis, liver damage, and others [32,33].”
Lewis, C. P., Klimes‐Dougan, B., Croarkin, P. E., & Cullen, K. R. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02168-2 · Cited by 34
Metadata
- Authors
- Sharp, T., & Collins, H.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Sharp, Trevor
- Venue
- Current Topics in Behavioral Neurosciences
- Publisher
- Springer International Publishing
- Published
- 2023
- Volume
- 66
- Pages
- 21-47
- ISSN
- 1866-3370 (ISSN-L)
- 1866-3389
- OpenAlex
- W4388641323
- Semantic Scholar
- 552e950a7b67d0c9226bf70575d04b14cc9a3a47
- Cited by
- 55
- References
- 138
- Citations by year
- 2026: 24 · 2025: 28 · 2024: 3
- FWCI
- 51.18
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Current topics in behavioral neurosciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- selective serotonin reuptake inhibitors, antidepressant mechanism, serotonin, neuroplasticity, rapid-acting antidepressants, ketamine, psychedelics, mood regulation
- MeSH terms
- Animals, Antidepressive Agents, Humans, Neuronal Plasticity, Serotonin, Substance Withdrawal Syndrome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.